Category Archives: Transhuman News

The same ingredients in soap that break apart dirt and oils can also strip moisture and softness from your skin. To restore moisture, dairy ingredients like cows milk are sometimes added to the mix of your favorite bar soaps. Goats milk soap is simply a bar soap that has goats milk in the formula instead of cows milk.

Like other natural soaps, goats milk soap is made from lye thats mixed with fats and oils. In this case, the fats in the soap come at least in part from goats milk.

Since goats milk has a different molecular structure than cows milk, some people with a cows milk sensitivity prefer it. Goats milk may have some immune-boosting and other benefits if you drink it, and some people believe that using it topically in the form of soap can provide the same benefits for skin conditions like eczema.

Theres little research that proves goats milk soap will work to treat eczema.

Heres what we do know about using goats milk soap, including whether its a safe home remedy for children and adults with eczema.

Goats milk soap hasnt been extensively tested for use as an eczema treatment. Here are the proven benefits of goats milk soap and how they might play into eczema treatment.

Goats milk contains lactic acid, a naturally occurring and gentle alpha-hydroxy acid (AHA). Lactic acid is even in some commercial-grade skin peels because of how effective it is at exfoliating and encouraging cell turnover. Cleansing your skin with goat milk soap may help dissolve dead skin cells, revealing healthy, younger skin cells underneath.

Lactic acid from goat milk also contains probiotics. Oral probiotics using lactic acid bacteria have been shown to help treat eczema in infants. Since these probiotics found in the lactic acid found in goat milk was an effective topical treatment in infants, it might be worth a try.

Lactic acid doesnt just add probiotics and exfoliate your skin. Lactic acid in goats milk, combined with the natural fats and oils in the milk, are a natural humectant. That means that goats milk soap may strengthen your skin barrier and seal moisture in. Skin thats well-hydrated may be more resistant to eczema flareups.

Goats milk soap is generally considered safe for everyone. That includes the soft, extra-sensitive skin of babies and children.

Youll also want to look at the other ingredients. If you have eczema, you may be all too familiar with cosmetics, soaps, and beauty products that claim to be all natural but trigger your symptoms and inflame your skin. Also be aware of what type of oils are contained in the soap. At least one study indicates that olive oil can make eczema symptoms worse for babies.

If youre considering bathing your little one with goats milk soap, run it by their pediatrician, especially if your baby is less than 1 year old. Also, keep in mind that goats milk soap is not a replacement for any skincare product a doctor has prescribed for your baby to treat eczema or psoriasis.

Some kids might have sensitivity to goats milk soap, so use a small amount the first time to test it out.

Goats milk soap works great for some people, but it isnt for everyone. A study published in 2017 noted that using goats milk soap for inflammatory skin conditions, such as eczema, may increase your likelihood of developing an allergic reaction to consuming goats milk and goats milk products. Research also suggests that absorbing certain ingredients through a compromised skin barrier can lead to food allergies later on.

If youre interested in using goats milk soap for eczema, you have a couple of options.

First, you need to find the right products. Goats milk soap can be made from a powder base, or from fresh goats milk. Anecdotally, people who swear by goats milk for eczema prefer fresh goats milk for maximum benefits.

If youd rather test your skins reaction to goats milk soap (or if youre trying it out on an infant), you can simply add a little bit of the soap to warm water in the tub to create a soothing bath. Just make sure to keep it away from infants eyes.

Goats milk soap is more readily available in the United States than its ever been.

You can buy goats milk soap at health food stores, natural beauty suppliers, organic supermarkets, and some pharmacies.

Shop for goat milk soap online.

The evidence we have to support using goats milk soap for eczema is mainly anecdotal. However, theres research to support other benefits of goats milk soap for your skin, some of which are linked to eczema management.

For most people, theres little harm in giving goats milk soap a try to treat eczema symptoms. If you have a goats milk allergy, you may want to steer clear. Consult your childs pediatrician if you have questions about trying goats milk soap to help treat eczema for your child.

Visit link:
Goat's Milk Soap for Eczema: Potential Benefits and Precautions - Healthline

The Sarna Eczema Relief Whipped Foam helps heal eczema flare-ups and provides fast, soothing relief. Featuring eN2fused technology, a patent-pending matrix-infused technology containing millions of compressed gas microbubbles that rapidly expand when dispensed, the maximum strength formula helps to prevent transepidermal water loss and improve skin's natural protective barrier.

"Consumer demand has increased for more elegant formulations that absorb quickly into the skin without leaving unwanted residue," said Steve Gallopo, Crown Therapeutics Vice President, Global OTC Sales & Marketing. "Sarna has had tremendous success and is uniquely positioned to improve the anti-itch category. This first-of-its-kind whipped foamtechnology drives the brand to the forefront of best-in-class, innovative skin science solutions."

"Sarna has always been my go-to recommendation for patients suffering from dry, itchy skin and eczema," said Dr. Hadley King, Board Certified Dermatologist, "I'm thrilled to be able to offer a new, easy to use, fast-absorbing option that delivers the relief that my patients need, especially for those who want a more lightweight formula for everyday use."

Sarna Eczema Relief Whipped Foam is now available via Amazon.

1IQVIA Health

About SarnaSarna is the #1 dermatologist-recommended topical anti-itch brand1. Offering a unique variety of formulations, each product in the collection is designed to provide fast-acting, intensive relief and comfort to compromised skin without a prescription. Sarna products provide powerful itch relief and are safe for everyday use, containing no parabens, dyes or added fragrance. For more information about Sarna, please visithttps://sarnalotion.com/

About CrownCrown, a privately held, fully integrated global skin care company is committed to developing and providing a diverse portfolio of aesthetic, beauty, and therapeutic skin care products that improve the quality of life for its customers. An innovative company focused on skin science for life, Crown's unyielding pursuit of delivering therapeutic excellence and enhanced patient outcomes is why it has become a leader in Dermatology and Aesthetics. Crown has been listed on the Inc. 5000 Fastest Growing Privately Held Companies List for seven years and has expanded its distribution to over 38 countries. For more information about Crown or its products, visitwww.crownlaboratories.com.

SOURCE Crown Laboratories, Inc.

Home

Read this article:
Sarna Launches First-of-Its-Kind Whipped Foam Eczema Relief Therapy - PRNewswire

A real-world assessment of dupilumab (Dupixent) show the biologic agent provides patients with atopic dermatitis consistent clinician- and patient-reported outcomes.

The interim PROSE registry findings, presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience this weekend, complement a litany of clinical trials observing the interleukin-4 and -13 (IL-4; IL-13) inhibitor for atopic dermatitis.

Investigators, led by Jerry Bagel, MD, of the Psoriasis Treatment Center of Central New Jersey, sought the early trends of real-world initiated dupilumab treatment from the PROSE registryan ongoing, multicenter, longitudinal observational database enrolling atopic dermatitis patients treated with dupilumab in the US and Canada for up to 5 years.

Randomized dupilumab clinical trials have demonstrated rapid and sustained long-term efficacy with an acceptable safety profile in patients with moderate-to-severe atopic dermatitis; however, real-world data are limited, Bagel and colleagues wrote.

Their assessment of the registry did not include imputation for missing values. Eligible patients were initiating dupilumab as standard of care for diagnosed atopic dermatitis, but were able to receive marketed drugs as prescribed by clinicians for either their disease or a comorbid condition.

At the data cutoff of July 2019, 315 patients were enrolled. Mean patient age was 42.5 years old, with 44.8% being male, and 59.4% being White. Mean baseline Eczema Area Severity Index (EASI) score was 16.9; duration of atopic dermatitis was 19.7 mean years.

By month 6 of real-world dupilumab care, mean EASI score decreased to 4.4. Mean body surface area affected by atopic dermatitis dropped from 26.8% at baseline to 7.2% at 6 months.

Patient-Oriented Eczema Measure (POEM) scores decreased from 18.5 at baseline to 6.9 at month 6. Investigators additionally observed decreases in Peak Pruritus Numerical Rating Scale (6.9 vs 2.5) and Mean Dermatology Life Quality Index (12.7 vs 4.4) in the observed time period.

This real-world study demonstrates improvement in atopic dermatitis in adults over the initial 6 months of dupilumab treatment, using investigator-assessed and patient-reported outcomes, Bagel noted in his presentation.

The study, Early Trends of Disease Improvement in Adult Patients With Atopic Dermatitis Treated With Dupilumab: Real-World Data From the PROSE Registry, was presented at AAD VMX.

Read the rest here:
Real-World Dupilumab Initiation Linked to Atopic Dermatitis Clearance at 6 Months - MD Magazine

The CHMP positive opinion is one of the final steps before the European Commission makes its decision on the Marketing Authorization Application for use of Adtralza, an investigational therapy in clinical development, throughout the European Union. This final decision is expected in the coming months and if authorized, Adtralza will be the first fully human, monoclonal antibody available to specifically target the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms. Adtralza specifically targets IL-13 with high affinity and is developed to improve the symptoms of atopic dermatitis, which is a complex and chronic inflammatory skin condition.1,2

Atopic dermatitis is characterized by its unpredictability, which can be challenging for patients who often experience physical discomfort and emotional effects that may continue for decades, said Jrg Mller, Executive Vice President, Global Research and Development, LEO Pharma. Todays CHMP opinion brings LEO Pharma one step closer to the potential of providing Adtralza as a new therapeutic option for EU patients living with moderate-to-severe atopic dermatitis.

The CHMP opinion is based primarily on data from three pivotal randomized, double-blind, placebo-controlled trials (ECZTRA 1, 2 and ECZTRA 3), which evaluated the safety and efficacy of Adtralza as monotherapy and with concomitant topical corticosteroids (TCS) in more than 1,900 adult patients with moderate-to-severe atopic dermatitis. Primary endpoints were the Investigator Global Assessment score of clear or almost clear skin (IGA 0/1) and at least a 75% improvement in the Eczema Area and Severity Index score (EASI-75).3,4

Secondary endpoints, including the extent and severity of skin lesions, pruritus (itch), sleep and health-related quality of life measures, were measured by changes in the following scores: EASI-90, SCORing Atopic Dermatitis (SCORAD), Pruritus Numeric Rating Scale (NRS), Eczema-Related Sleep NRS and Dermatology Life Quality Index (DLQI). The trials demonstrated that Adtralza met the primary and secondary efficacy endpoints and was generally well tolerated.3,4

Pending the final decision from the European Commission, the marketing authorization will be valid in all European Union Member States, Iceland, Norway, and Liechtenstein. Additional regulatory filings are underway [with the U.S. Food and Drug Administration (FDA)] and other health authorities worldwide.

About Adtralza (tralokinumab)

Adtralza (tralokinumab) is a fully human, monoclonal antibody developed to specifically neutralize the IL-13 cytokine, which plays a key role in the immune process underlying atopic dermatitis signs and symptoms. Adtralza specifically binds to the IL-13 cytokine with high affinity, thereby preventing interaction with the IL-13 receptor 1 and 2 subunits (IL-13R1 and IL-13R2).1,2

About the pivotal ECZTRA 1, 2, and ECZTRA 3 Trials

ECZTRA 1 and ECZTRA 2 (ECZema TRAlokinumab trials Nos. 1 and 2) were randomized, double-blind, placebo-controlled, multinational 52-week trials, which included 802 and 794 adult patients, respectively, to evaluate the safety and efficacy of Adtralza (300 mg) as monotherapy in adults with moderate-to-severe atopic dermatitis who were candidates for systemic therapy.3

ECZTRA 3 (ECZema TRAlokinumab trial No. 3) was a double-blind, randomized, placebo-controlled, multinational 32-week trial, which included 380 adult patients, to evaluate the safety and efficacy of Adtralza (300 mg) in combination with TCS in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.4

About atopic dermatitis

Atopic dermatitis (AD) is a chronic, inflammatory, skin disease characterized by intense itch and eczematous lesions.5 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.6 Type 2 cytokines, including IL-13, play a central role in the key aspects of atopic dermatitis pathophysiology.1

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. [In 2020, the company generated net sales of DKK 10,133 million]. For more information please visit http://www.LEO-Pharma.com

References

April 2021 MAT-42443

View source version on businesswire.com: https://www.businesswire.com/news/home/20210423005296/en/

Continued here:
LEO Pharma Receives Positive CHMP Opinion of Adtralza (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis - BioSpace

The appearance of flushed skin around the nose varies from person to person. It can depend on the specific condition that causes it, how severe the irritation is, and a persons skin color.

Some people notice dry, itchy spots, raised or indented skin, or tiny blisters.

In people with dark skin, flushed skin around the nose may appear violet or purple. It may also be less noticeable, even when the rash is severe.

People with dark skin may also find that their doctors do not easily recognize the signs of various skin conditions. This may be due to dermatology textbooks that have focused on light-skinned patients.

For example, a 2020 study found that dermatologists might not recognize the skin manifestations of COVID-19 in Black patients. This can undermine their quality of care.

Learn about how rashes can look on dark skin here.

There are many different conditions or factors that could cause flushed skin around a persons nose.

Simply wiping the nose over and over can irritate the skin. This is especially the case during dry, cold months when the skin is more likely to be dry and irritated.

A person may notice that their skin looks red or purple, and the pain may worsen when they wipe their nose.

Some people develop mild allergic reactions to substances that touch their skin. Doctors call this contact dermatitis.

Irritant contact dermatitis irritates the skin but does not cause an allergic reaction. It may cause flushed skin and a raised rash, but the rash should not spread or cause a fever.

Causes of irritant contact dermatitis on the nose may include:

Symptoms of allergic contact dermatitis, such as a rash, may appear 2 days after a person has come into contact with an allergen.

Some causes may include fragrances and the preservative thimerosal, which features in some antibiotic creams.

Less commonly, a person may develop a life-threatening allergic reaction called anaphylaxis. This usually happens within a few minutes of exposure to an allergen.

Anaphylaxis may begin as a rapidly spreading rash. If a person sees a rash on their nose, they should check their body for bumps or other rashes.

Anaphylaxis is a medical emergency. If a person sees a spreading rash or has trouble breathing, they should call 911.

Rosacea is a skin condition that causes flushed skin and inflammation. While rosacea can affect any part of the body, it often begins around the nose.

A person might notice flushed skin, damaged blood vessels, tiny bumps, or changes in the shape of the nose. Rosacea is not dangerous, but it can affect a persons appearance.

In some people, rosacea may also be a sign of an underlying illness, such as an autoimmune disease.

Rosacea is more prevalent in people between the ages of 30 and 50 and in those with light skin. It is more likely to affect females than males.

Discover the best skin care products for rosacea here.

Eczema is a chronic inflammatory skin condition that causes dry, irritated patches of skin.

Sometimes the irritation is so severe that the patches crack open and bleed. Allergens and irritation can trigger an eczema flare, but dry skin is also a common culprit.

Redness around the nose may be eczema if it feels dry and itchy, looks white, red, or flaky, and worsens when the skin is dry.

Learn about what eczema can look like on black skin here.

A person can develop a sunburn just around their nose if they:

If the redness is flat and turns flesh-colored when a person presses on it, it may be a sunburn.

Sunburn may also feel dry and very sore. Severe sunburns sometimes blister.

Sunburn is a risk factor for skin cancer.

African American people have a lower melanoma survival rate than Caucasians. This may be due to delays in care.

Learn about how sunburn affects dark skin here.

An infection at the entrance of the nose called nasal vestibulitis can cause flushed skin and tiny, blister-like bumps around the nose and just inside of it.

A person may feel pain, swelling, and intense sensitivity. Some people develop a fever, though a person does not have to have a fever to have vestibulitis.

Nasal vestibulitis happens when bacteria enter the skin of the nose, often following an injury or infection. It can happen after a person trims their nose hairs.

Nasal vestibulitis is easy to treat, but it can spread to other areas of the body, so it is important to see a doctor.

Veins, which carry blood back to the heart, have valves in them to prevent blood from flowing the wrong way.

However, when these valves become damaged, the veins may look damaged and twisted. These are known as varicose veins.

Varicose veins often occur in the legs and feet. They especially happen in pregnant people and those who are overweight or obese. However, a person can develop varicose veins anywhere, including the nose.

The nose may look red, but when a person looks more closely, they might see tiny damaged blood vessels.

Learn 10 home remedies for varicose veins here.

Lupus is an autoimmune condition that causes the body to attack healthy tissue, leading to a wide range of symptoms and chronic illnesses.

Some people with lupus develop a malar rash, also known as a butterfly rash because it resembles a butterfly. This rash can cover the nose and cheeks.

In some cases, the butterfly rash may be the first symptom of lupus.

Learn about more symptoms of lupus here.

Infections of the skin can cause red, painful skin that may feel hot to the touch.

Cellulitis, one such infection, can begin with an injury even a small one. It might be as simple as dry, cracked skin. Bacteria gets into the deep layer of skin, called the dermis, and begins spreading. A person might notice flushed streaks, heat, pain, or swelling.

Bacterial skin infections can spread to other areas of the body, potentially even endangering a persons life. Therefore, it is important to seek prompt care.

See pictures of skin infections here.

Continued here:
Redness around nose: Causes, treatment, home remedies, and more - Medical News Today

Published April 26, 2021 by Tamsin Hackett

Ebury Press will publish singerEmma Bunton's first book, Mama You Got This, on 10th June 2021.

Ebury Press will publish singerEmma Bunton's first book, Mama You Got This, on 10th June 2021.

Laura Higginson, editorial director, bought world all language rights from Severine Berman at The Mutha Ship.

Bunton is a mum of two and like most new parents, she juggled being a working mum, partner, friend, and trying to find time for herself, says the publisher. Although she had supportive friends and family, she found the endless rules and strict routines of most baby books overwhelming.

Mama You Got This is the book Bunton wishes she had readwhen she was a new mum.She will share the highs and lows she experienced,from post-birth recovery and no sleep to playtime and first smiles and share what she has learnt and some funny stories along the way. The author will also discuss her baby-care range Kit & Kin which she launched in 2017 after her child Tate suffered with chronic eczema.

The information in the book will be backed by experts including Yales paediatric sleep consultant Dr Craig Canapari, NCT breastfeeding expert Fran Bailey, mindfulness coach Heidi Fultonand midwife Marley Hall who will offer tips aboutsleeping, breastfeeding, weaning, crying, feeding, playing and self-care.

Higginson said: "Emma is known for being Baby Spice, full of girl power. I loved hearing about the very personal other side of her life and all those secret stories from being a mum whilst being one of the most famous pop stars on the planet. Her motivation for launching Kit and Kinto make a positive difference to baby-care and the planet is really inspiring and Emmas passion to write an equally positive, accessible modern guide is really exciting its a modern mum bible rich with relatable stories that will leave readers laughing, crying and feeling like whatever they are dealing with, they are not alone and there is help."

Bunton commented: "For my first ever book, writing about the most important part my life was easy. Opening up and sharing my stories feels totally natural with all you mums who are going through the same experiences but all in our own unique way. Becoming a mummy can be so daunting but we are in this together and we can support each other, dont you worry, mama,youve got this!"

The rest is here:
Ebury to spice up the summer with Bunton's 'modern mum bible' - The Bookseller

When the pandemic really started to take a stranglehold on Jamaica, I made a decision to try and grow a beard.

I even wrote about it here in this column. Now that decision came after months of not going to the barbershop because mi nuh waan ketch COVID jus because me a try look decent. I realised that the old facial hair had grown so much, it didnt feel right to get rid of it.

Then I started perusing social media and the Internet to see what hairstyles would complement the new look. Found something I thought would work. First time I went to the barber circa August (remember COVID reach yah March) I felt boasy. Even posted on social media and everything.

But its been all downhill since then. You see, I have a little issue called eczema but when all the creams and medicinal shampoos are working its all good. But once that hair starts to get to a certain height and thickness, God help you! Then before you know, because of work and other stresses, the hair washing and maintenance schedule gets thrown out of whack. So instead of washing the hair twice a week, you end up doing it once a week. And whereas in the early weeks of the growth you knew the hair-care products were getting to the scalp, it turns out to be less so as the hair gets more clumped.

So the semi-matted look became just matted and messy real quick. And like I said, yours truly has an eczema issue. As anyone who knows about that stuff will tell you, stress and other factors like failure to keep the scalp moisturised, will have rather negative effects. I found that out the hard way recently. Had to go to the barber and bruh, it was not pretty. Good thing my barber is cool (Dre big up yuhself) because my head never look good at all! I felt like Naaman the leper in the Bible.

Since then Ive been using a regimented schedule of washing the rapidly re-growing hair (I decided to shave it bald) and using good ol aloe vera to keep things presentable. Ill update you on how its going another time.

The reason for the column this week is to tell all of us who like to criticise women for doing what we consider too much for beauty, should really shut up. Look, it takes work to keep yourself looking decent. Note Im not talking about looking glamorous. Im just talking about looking normal. Even if youre only using natural products, you have to be disciplined. So if we are talking about even more exotic looks, it must take even more effort. We all have the right to feel good about ourselves. So if some people, especially women, put tremendous labour into their appearance, even if we dont think it looks good, who are we to judge?

Everyone should be free to look their best, regardless of what they consider their best to be.

Link me at daviot.kelly@gleanerjm.com

See more here:
Can't argue with women on this beauty thing - Jamaica Gleaner

INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY) and Incyte's (NASDAQ:INCY) OLUMIANT (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate to severe atopic dermatitis (AD). In one BREEZE-AD5 analysis, OLUMIANT provided concurrent improvements in the severity and extent of AD, other key symptoms and quality of life as early as one week, as measured by percent change from baseline compared to placebo. In a separate BREEZE-AD5 analysis, adults with AD on 10-50% of their bodies at baseline who were treated with OLUMIANT showed significant improvements in the severity and extent of disease compared to placebo. In the integrated safety analysis of eight AD studies of OLUMIANT, there were no increases in rates for treatment-emergent adverse events, serious adverse events or serious infections with long-term OLUMIANT therapy compared to the placebo-controlled period. These results are being presented virtually at the American Academy of Dermatology's Virtual Meeting Experience (AAD VMX), April 23-25, 2021.

"Atopic dermatitis is the most common chronic, inflammatory skin disease among adults and can pose significant challenges for those who suffer from this debilitating disease," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "We are encouraged by these additional new analyses of the BREEZE-AD5 study results, in which OLUMIANT showed early improvement across multiple symptoms among patients with moderate to severe atopic dermatitis. We are pleased the extended safety analysis helps further define the long-term safety profile of OLUMIANT in atopic dermatitis."

OLUMIANT 2-mg Concurrently Improved Extent, Severity and Key Symptoms of AD in as Early as One Week

In a post-hoc analysis of BREEZE-AD5, patients treated with OLUMIANT 2-mg showed statistically significant and concurrent improvements in the extent and severity of AD, as well as key symptoms such as itch, nighttime awakenings due to itch, skin discomfort and pain, and quality of life, as early as one week as measured by percent change from baseline compared to placebo. Patients taking OLUMIANT had statistically significant improvements from baseline (p<0.05) across all measures compared to placebo at one week and four weeks:

For methodology, see "About the Analyses" section below.

Patients with AD on 10-50% of Their Bodies at Baseline Treated with OLUMIANT 2-mg Experienced Significant Improvements in Severity and Extent of AD

A post-hoc analysis of BREEZE-AD5 was conducted to evaluate the efficacy of OLUMIANT 2-mg based on baseline Body Surface Area (BSA), which measures the extent to which a patient's skin is affected by AD. At two weeks, 2 out of 10 patients with a BSA 10-50% at baseline who were treated with OLUMIANT saw significant improvements in the severity and extent of their AD compared to placebo (20.2% vs. 5.9%, p0.01), as measured by a 75% improvement in Eczema Area Severity Index (EASI 75).

At 16 weeks, nearly 4 out of 10 patients with a BSA 10-50% at baseline who were treated with OLUMIANT saw significant improvements in the severity and extent of their AD compared to placebo (37.5% vs. 9.9%, p0.001) as measured by EASI 75.

At 16 weeks, approximately 3 out of 10 patients with a BSA 10-50% at baseline who were treated with OLUMIANT saw significant improvements in the severity and extent of the AD compared to placebo (31.7% vs. 6.9%, p0.001) based on achievement of clear or almost clear skin, as measured by the validated Investigator Global Assessment for Atopic Dermatitis [vIGA-AD (0,1)].

OLUMIANT was also evaluated in patients with BSA >50% at baseline. Among these patients, results for OLUMIANT were numerically higher but not statistically significant compared to placebo. Safety for the baseline BSA 10-50% subgroup was consistent with the overall safety population across the OLUMIANT clinical program in AD.

For methodology, see "About the Analyses" section below.

"Patients with moderate to severe atopic dermatitis may have different treatment needs given the extent and severity of their disease," said Eric Simpson, M.D., M.C.R., Professor of Dermatology and Director of Clinical Research at Oregon Health & Science University in Portland and co-author of these analyses. "These results are exciting because they can help provide more clarity to dermatologists on how patients with atopic dermatitis on 10-50% of their bodies may respond to a systemic therapy, such as OLUMIANT."

Long-Term Analysis Supports Safety Profile of OLUMIANT 2-mg in AD

The safety profile for OLUMIANT 2-mg was evaluated in eight AD clinical studies (six double-blind, randomized, placebo-controlled studies and two long-term extension studies). In the 16-week placebo-controlled period, there was no observed increase in rates of serious adverse events or serious infections with OLUMIANT therapy compared to placebo, and rates remained similar in the long-term extensions. There were no reports of deep vein thrombosis and pulmonary embolism across these studies.

OLUMIANT showed no increase in anemia, neutropenia, lymphopenia or elevated liver enzymes compared to placebo as measured by mean change from baseline, and there was no additional increase in these lab changes with long-term therapy.There was no increase in risk of eczema herpeticum with OLUMIANT compared to placebo (0.2% vs. 0.4%), but an increase in cases of herpes simplex (2.0% vs. 0.9%) was observed.

For methodology, see "About the Analyses" section below.

"Given how challenging this multidimensional disease is to treat, patients with AD need additional options that can help them manage their disease when other therapies have not been effective," Dr. Mallbris continued. "OLUMIANT has the potential to be the first oral JAK inhibitor approved for adults with moderate to severe atopic dermatitis in the U.S. When approved, it would also have one of the largest sets of available safety data in its class for AD."

About The Analyses

OLUMIANT, an oral JAK inhibitor discovered by Incyte and licensed to Lilly, is currently under review by the U.S. Food and Drug Administration as an investigational medication for the treatment of adults with moderate to severe AD. Outside the U.S., it is the first JAK inhibitor approved for AD in more than 40 countries. It is also being investigated for the treatment of adults with alopecia areata, systemic lupus erythematosus, juvenile idiopathic arthritis, COVID-19 and for its approved indication for rheumatoid arthritis.

About OLUMIANTOLUMIANT is a once-daily, oral JAK inhibitor approved in theU.S.and more than 70 countries as a treatment for adults with moderate to severe rheumatoid arthritis (RA). It is also approved in theEuropean Union, Japanand other countriesfor the treatment of adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. TheU.S.FDA-approved labeling for Olumiant includes a Boxed Warning for Serious Infections, Malignancy, and Thrombosis. See the full Prescribing Informationhere.

InDecember 2009,LillyandIncyteannounced an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib and certain follow-on compounds for patients with inflammatory and autoimmune diseases.

Indication and Usage for OLUMIANT (baricitinib) tablets (in the United States) for RA patients

OLUMIANT(baricitinib) 2-mg is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Limitation of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

IMPORTANT SAFETY INFORMATION FOR OLUMIANT (baricitinib) tablets

WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS

SERIOUS INFECTIONS: Patients treated with Olumiant are at risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt Olumiant until the infection is controlled. Reported infections include:

Carefully consider the risks and benefits of Olumiant prior to initiating therapy in patients with chronic or recurrent infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with Olumiant including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

MALIGNANCIES: Lymphoma and other malignancies have been observed in patients treated with Olumiant.

THROMBOSIS: Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed at an increased incidence in patients treated with Olumiant compared to placebo. In addition, there were cases of arterial thrombosis. Many of these adverse events were serious and some resulted in death. Patients with symptoms of thrombosis should be promptly evaluated.

WARNINGS AND PRECAUTIONS

SERIOUS INFECTIONS:The most common serious infections reported with Olumiant includedpneumonia, herpes zoster, and urinary tract infection. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus were reported with Olumiant. Some patients have presented with disseminated rather than localized disease, and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids. Avoid Olumiant in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating Olumiant in patients:

Closely monitor patients for infections during and after Olumiant treatment. Interrupt Olumiant if a patient develops a serious infection, an opportunistic infection, or sepsis. Do not resume Olumiantuntil the infection is controlled.

Tuberculosis Before initiating Olumiant,evaluate and test patients for latent or active infection and treat patients with latent TB with standard antimycobacterial therapy. Olumiant should not be given to patients with active TB. Consider anti-TB therapy prior to initiating Olumiant in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Monitor patients for TB during Olumiant treatment.

Viral Reactivation Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies with Olumiant. If a patient develops herpes zoster, interrupt Olumiant treatment until the episode resolves.

The impact of Olumiant on chronic viral hepatitis reactivation is unknown. Screen for viral hepatitis in accordance with clinical guidelines before initiating Olumiant.

MALIGNANCY AND LYMPHOPROLIFERATIVE DISORDERS:Malignancies were observed in Olumiant clinical studies. Consider the risks and benefits of Olumiant prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing Olumiant in patients who develop a malignancy. NMSCs were reported in patients treated with Olumiant. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.

THROMBOSIS:Thrombosis, including DVT and PE, has been observed at an increased incidence in Olumiant-treated patients compared to placebo.In addition, arterial thrombosis events in the extremities have been reported in clinical studies with Olumiant. Many of these adverse events were serious and some resulted in death. There was no clear relationship between platelet count elevations and thrombotic events. Use Olumiantwith caution in patients who may be at increased risk of thrombosis. If clinical features of DVT/PE or arterial thrombosis occur, evaluate patients promptly and treat appropriately.

GASTROINTESTINAL PERFORATIONS:Gastrointestinal perforations have been reported in Olumiant clinical studies, although the role of JAK inhibition in these events is not known. Use Olumiantwith caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis). Promptly evaluate patients who present with new onset abdominal symptoms for early identification of gastrointestinal perforation.

LABORATORY ABNORMALITIES:

Neutropenia Olumiant treatment was associated with an increased incidence of neutropenia (absolute neutrophil count [ANC] <1000cells/mm3) compared to placebo. Avoid initiation or interrupt Olumiant treatment in patients with an ANC <1000cells/mm3. Evaluate at baseline and thereafter according to routine patient management.

Lymphopenia Absolute lymphocyte count (ALC) <500cells/mm3were reported in Olumiant clinical trials. Lymphocyte counts less than the lower limit of normal were associated with infection in patients treated with Olumiant, but not placebo. Avoid initiation or interrupt Olumiant treatment in patients with an ALC <500cells/mm3. Evaluate at baseline and thereafter according to routine patient management.

Anemia Decreases in hemoglobin levels to <8g/dL were reported in Olumiant clinical trials. Avoid initiation or interrupt Olumiant treatment in patients with hemoglobin <8g/dL. Evaluate at baseline and thereafter according to routine patient management.

Liver Enzyme Elevations Olumiant treatment was associated with increased incidence of liver enzyme elevation compared to placebo. Increases of ALT 5x upper limit of normal (ULN) and increases of AST 10x ULN were observed in patients in Olumiant clinical trials.

Evaluate at baseline and thereafter according to routine patient management. Promptly investigate the cause of liver enzyme elevation to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt Olumiant until this diagnosis is excluded.

Lipid Elevations Treatment with Olumiant was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol. Assess lipid parameters approximately 12weeks following Olumiant initiation. Manage patients according to clinical guidelines for the management of hyperlipidemia.

VACCINATIONS: Avoid use of live vaccines with Olumiant. Update immunizations in agreement with current immunization guidelines prior to initiating Olumiant therapy.

HYPERSENSITIVITY:Reactions such as angioedema, urticaria, and rash that may reflect drug sensitivity have been observed in patients receiving Olumiant, including serious reactions. If a serious hypersensitivity reaction occurs, promptly discontinue Olumiant while evaluating the potential causes of the reaction.

ADVERSE REACTIONSAdverse reactions (occurring in 1% of Olumiant-treated patients in placebo-controlled trials) include: upper respiratory tract infections, headache, abdominal pain, nausea, herpes simplex, urinary tract infection, acne, and herpes zoster.

USE IN SPECIFIC POPULATIONS

PREGNANCY AND LACTATION:No information is available to support the use of Olumiant in pregnancy or lactation. Advise women not to breastfeed during treatment with Olumiant.

HEPATIC AND RENAL IMPAIRMENT:Olumiant is not recommended in patients with severe hepatic impairment or in patients with severe renal impairment.

Pleaseclickto accessfullPrescribing Information,including Boxed Warning about Serious infections, Malignancies, and Thrombosis, andMedication Guide.

BA HCP ISI 09JUL2020

About Atopic DermatitisAtopic dermatitis (AD), or atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body.1AD is a heterogeneous disease both biologically and clinically, but may be characterized by a highly variable appearance in which flares occur in an unpredictable manner.

Moderate to severe AD is characterized by intense itching, which leads to an itch-scratch cycle that further damages the skin.1 Like other chronic inflammatory diseases, AD is immune-mediated and involves a complex interplay of immune cells and inflammatory cytokines.2

About Lilly in DermatologyBy following the science through unchartered territory, we continue Lilly's legacy of delivering innovative medicines that address unmet needs and have significant impacts on people's lives around the world. Skin-related diseases are more than skin deep. We understand the devastating impact this can have on people's lives.At Lilly, we are relentlessly pursuing a robust dermatology pipeline to provide innovative, patient-centered solutions so patients with skin-related diseases can aspire to live life without limitations.

About Eli Lilly and CompanyLilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom.

About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

OLUMIANT is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. P-LLY

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about OLUMIANT (baricitinib) as a treatment for patients with rheumatoid arthritis and a possible treatment for patients with atopic dermatitis and other conditions and reflects Lilly's and Incyte's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of research, development, and commercialization. Among other things, there can be no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with the results to date, and that OLUMIANT will receive additional regulatory approvals, or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's and Incyte's most recent respective Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly and Incyte undertake no duty to update forward-looking statements to reflect events after the date of this release.

SOURCE Eli Lilly and Company

http://www.lilly.com/

Here is the original post:
OLUMIANT Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses...